Veloxis has appointed Ulf Meier-Kriesche as its Chief Scientific Officer and he will oversee the Danish company’s regulatory and medical affairs departments. This is according to a press release from Veloxis.
The new CSO is a board certified nephrologist, specialist in medical kidney diseases, with more than 20 years of practical clinical experience in transplantation. And this is also the main focus for Veloxis’, as its main asset Envarus XR is used to prevent organ rejection in patients who have undergone a kidney or liver transplantation.
Mere fra MedWatch
Hørekoncernen Sonova nedjusterede tirsdag forventningerne til helåret som følge af den aktuelle uro på markederne verden over, men turbulensen får ikke selskabet til at udskyde planerne om inden længe at lancere en ny produktplatform. ”Det er vigtigt, at vi positionerer os stærk overfor konkurrenterne”.